GlassScriptPhysician profile
Troy R Baker
NPI 1487624664
$1,415.13
in general payments reported to CMS, 2019-2025
21 companies · $96.12 in 2025
The $96.12 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $351 · 2023: $428 · 2024: $414 · 2025: $96.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $430.99 | 2022-2025 | Vraylar |
| Lilly USA, LLC | $233.13 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $161.18 | 2021-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $131.37 | 2023-2025 | |
| Cranial Technologies, INC | $55.36 | 2021-2024 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $50.85 | 2023-2024 | Airsupra, Farxiga |
| Boston Scientific Corporation | $48.60 | 2023 | Wavewriter Alpha Prime 16 |
| Idorsia Pharmaceuticals US INC | $34.57 | 2022-2023 | Quviviq |
| Organon LLC | $31.81 | 2021-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $29.74 | 2022-2023 | Steglatro, Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $29.54 | 2022 | |
| Dexcom, INC. | $25.18 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $23.84 | 2025 | Auvelity |
| Becton, Dickinson and Company | $23.24 | 2022 | |
| Genentech USA, INC. | $17.89 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $16.75 | 2024 | Bd Onclarity |
| Sanofi-Aventis U.S. LLC | $16.08 | 2022 | |
| Lucid Diagnostics INC. | $14.57 | 2022 | |
| Antares Pharma, INC. | $14.31 | 2022 | |
| Adlon Therapeutics L.P. | $14.22 | 2021 | |
| Eisai INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.